| 000 | 01470ngm a2200337 a 4500 | ||
|---|---|---|---|
| 001 | HST2288_1_2 | ||
| 003 | UkLoHST | ||
| 006 | m c | ||
| 007 | cr|cna|||a|||| | ||
| 007 | vz|czazum | ||
| 008 | 080121s2009 enk|||||||||||s|||v|eng d | ||
| 028 | 5 | 0 |
_a2288 _bHenry Stewart Talks |
| 035 | _a(UkLoHST)1322 | ||
| 035 | _a(UkLU-K)001155639 | ||
| 040 |
_aUkLU-K _beng _cUkLU-K |
||
| 100 | 1 |
_aTang, Patricia, _u(Tom Baker Cancer Centre, Calgary, Canada) _4spk |
|
| 245 | 1 | 0 |
_aEmerging trends in phase II trial design _h[electronic resource] / _cPatricia Tang. |
| 260 |
_aLondon : _bHenry Stewart Talks, _c2009. |
||
| 300 |
_a1 online resource (1 streaming video file (42 min.) : _bcolor, sound). |
||
| 490 | 1 |
_aCancer therapy : latest thinking in efficacy and toxicity, _x2056-452X |
|
| 500 | _aAnimated audio-visual presentation with synchonized narration. | ||
| 500 | _aTitle from title frames. | ||
| 505 | 0 | _aContents: Purpose of phase II trials -- Advantages and disadvantages of common phase II trial designs -- Incorporation of correlative studies. | |
| 506 | _aAccess restricted to subscribers. | ||
| 538 | _aMode of access: World Wide Web. | ||
| 650 | 2 |
_aNeoplasms _xcomplications. |
|
| 650 | 2 |
_aNeoplasms _xtherapy. |
|
| 830 | 0 |
_aHenry Stewart talks. _pBiomedical & life sciences collection. _pCancer therapy : latest thinking in efficacy and toxicity. |
|
| 856 | 4 | 0 | _uhttps://hstalks.com/bs/1322/ |
| 856 | 4 | 2 |
_uhttps://hstalks.com/bs/p/385/ _3Series |
| 999 |
_c77746 _d77746 |
||